Current Drug Therapy
metrics 2024
Advancing the Frontiers of Pharmacological Research
Introduction
Current Drug Therapy is a pivotal journal in the field of pharmacology, published by Bentham Science Publishers Ltd. based in the United Arab Emirates. With an ISSN of 1574-8855 and an E-ISSN of 2212-3903, this journal serves as a vital platform for disseminating scholarly works that focus on the latest advancements and therapeutic applications within drug therapy. Operating without Open Access, it consistently attracts a diverse readership including researchers, healthcare professionals, and students eager to explore comprehensive reviews, original research articles, and critical insights into current trends and technologies from 2007 to 2024. Maintaining a steady presence in the competitive landscape, the journal's category quartiles reflect its growing significance, with rankings of Q4 in Pharmacology (medical) and Q3 in the broader scopes of Pharmacology, Toxicology, and Pharmaceutics as of 2023. Its contribution to the discourse in the domains of General Pharmacology, Toxicology and Pharmaceutics is underscored by its Scopus rank of #54 out of 80 in its category. Current Drug Therapy is not merely an academic resource; it is a beacon for innovation and a forum for critical dialogue that fosters the exchange of cutting-edge ideas in medication therapy, making it an essential read for professionals at the forefront of pharmaceutical Sciences.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Drug Target Insights
Pioneering Open Access to Critical Pharmacological Research.Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.
ACTA POLONIAE PHARMACEUTICA
Elevating Pharmaceutical Sciences with Every IssueACTA POLONIAE PHARMACEUTICA is a well-established peer-reviewed journal published by Polskie Towarzystwo Farmaceutyczne, dedicated to the field of pharmaceutical sciences and pharmacology. With a rich history dating back to 1951, this journal serves as a vital platform for disseminating cutting-edge research and developments in pharmaceutical technology, drug development, and therapeutic therapies. Although it currently operates under a subscription model, its commitment to scientific rigor has earned it a respectable impact factor, placing it in the Q3 and Q4 quartiles respectively for Pharmaceutical Science and Pharmacology as of 2023. Researchers and practitioners alike will find value in its comprehensive coverage of essential topics, as well as its diverse range of contributions from both established and emerging scholars in the field. With its address located in the heart of Warsaw, Poland, ACTA POLONIAE PHARMACEUTICA aims to further bridge the gap between academia and industry, paving the way for innovation in drug discovery and therapeutic applications.
MOLECULAR THERAPY
Advancing molecular medicine for a healthier tomorrow.MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.
Drug Discoveries and Therapeutics
Bridging research and practice in drug therapeutics.Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.
PHARMACIA
Advancing pharmaceutical knowledge for a healthier tomorrow.PHARMACIA is a distinguished open-access journal, published by PENSOFT PUBLISHERS, that has been a pivotal platform for advancing the field of pharmaceutical sciences since 2007. This journal, with ISSN 0428-0296 and E-ISSN 2603-557X, is based in Bulgaria and continues to publish high-quality research and reviews relevant to pharmacy, pharmacology, and toxicology. Recognized in the Q3 category for Pharmaceutical Sciences and Pharmacology (medical), as well as Q2 in Pharmacy according to the latest rankings, PHARMACIA is celebrated for its commitment to fostering knowledge dissemination and innovation in drug development, therapeutic approaches, and pharmacological research. With a Scopus rank of #17 in Pharmacy and recognition in various health professions, the journal attracts contributions from researchers, professionals, and students seeking to impact the pharmaceutical landscape. Its convenient open-access format ensures that articles are readily available to a global audience, encouraging collaboration and advancement in the life sciences.
Research in Pharmaceutical Sciences
Transforming Discoveries into Therapeutic SolutionsResearch in Pharmaceutical Sciences is a premier, peer-reviewed journal published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of pharmacology, toxicology, and pharmaceutics. With an impact factor that positions it in the second quartile of its category (Q2) and a respectable rank of 23 out of 80 in Scopus, this journal serves as an essential platform for researchers, professionals, and students alike, providing open access since 2015 to a wealth of pioneering studies and comprehensive reviews. Based in Mumbai, India, the journal encompasses a diverse range of topics within the pharmaceutical sciences, offering insights that address both theoretical and practical challenges in drug development and safety. As it converges from 2009 to 2024, Research in Pharmaceutical Sciences continues to be a vital source of knowledge, promoting innovation and fostering collaboration within the global scientific community.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Transforming therapeutic research into real-world applications.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.
MEDICINE
Advancing medical knowledge for a healthier tomorrow.MEDICINE, published by Lippincott Williams & Wilkins, is an esteemed open access journal in the field of general medicine, holding a significant position with a Scopus rank of #190 out of 636 in its category (2023), placing it in the 70th percentile. Since its inception in 1922, MEDICINE has been a vital platform for researchers, professionals, and students to disseminate groundbreaking findings and advancements in the medical field. With the transition to open access in 2014, the journal ensures that valuable research is readily available to a global audience, fostering collaboration and innovation across diverse medical disciplines. Its current impact factor and influence in the miscellaneous medicine category (Q3) reflect its commitment to supporting rigorous peer-review processes and promoting scholarly excellence. Located in Philadelphia, PA, the journal covers a wide range of topics, making it a crucial resource for those dedicated to the betterment of healthcare and medical education.
Natural Products Journal
Unveiling Nature's Secrets for Innovative MedicineNatural Products Journal, a leading publication by Bentham Science Publishers, primarily focuses on the rapidly evolving field of Natural Products and their applications in Complementary and Alternative Medicine as well as Drug Discovery. With an ISSN of 2210-3155 and an E-ISSN of 2210-3163, this journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the critical role of natural compounds in health and medicine. Since its inception in 2011, it has consolidated its reputation, achieving a Q3 ranking in Complementary and Alternative Medicine and a Q4 ranking in Drug Discovery as of 2023, illustrating its growing influence within the academic community. Although it currently does not operate as an Open Access journal, it remains a vital resource for cutting-edge research and developments in natural products, offering insightful contributions that pave the way for innovative therapeutic strategies. Located in the Netherlands, the journal is pivotal for those looking to stay at the forefront of research in natural substances and their multifaceted applications.
European Journal of Pharmacology
Shaping the future of pharmacology through impactful scholarship.The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.